JP4131443B2 - Anti-osteoporosis composition - Google Patents
Anti-osteoporosis composition Download PDFInfo
- Publication number
- JP4131443B2 JP4131443B2 JP2001256462A JP2001256462A JP4131443B2 JP 4131443 B2 JP4131443 B2 JP 4131443B2 JP 2001256462 A JP2001256462 A JP 2001256462A JP 2001256462 A JP2001256462 A JP 2001256462A JP 4131443 B2 JP4131443 B2 JP 4131443B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- bone
- osteoporosis
- test
- bone meal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、有効成分としてビタミンKと骨粉、特に魚骨粉を含有する抗骨粗鬆症組成物に関する。
【0002】
【従来の技術】
近年、社会の高齢化に伴い、骨密度が低下し骨がもろくなる骨粗鬆症が大きな問題となっている。骨粗鬆症になると骨の湾曲や激しい痛み、骨折などの症状がみられ、特に大腿骨頚部を骨折した場合では寝たきりとなることがあり、有効な治療方法が求められている。
骨粗鬆症の治療薬としては活性型ビタミンD3や女性ホルモン(エストロゲン)、カルシトニン、イプリフラボン、ビスフォスフォネート、ビタミンKなどが開発されているが、骨粗鬆症の治療は困難な場合が多く、適切な運動や日常摂取する食品に気をつける事により予防に努めることが重要である。
【0003】
骨粗鬆症を防ぐためには、食事に関して言えばカルシウムを多く含む乳製品や魚類の摂取が推奨されている。さらにカルシウムやマグネシウム、ビタミンDや、カゼインホスホペプチド(腸管からのカルシウムの吸収を促進する作用があると言われている)などを含む健康食品の利用も推奨されている。
近年、ビタミンKの骨に対する作用が注目され、色々な利用方法が検討されるようになってきた。ビタミンKには、主として植物が作るビタミンK1(フェロキノン)と主として微生物が作るビタミンK2(メナキノン)があるが、さらにビタミンK2は側鎖の長さの違いによりメナキノン(MK)−1〜14に分類されている。ビタミンKは食品中に広く存在するが、その含量はごく微量である。
一方、最近になって、ウナギ骨微粉末等の魚骨粉に骨の改善作用があることがわかり注目されている。
【0004】
【発明が解決しようとする課題】
ビタミンKは、食品中に極微量含まれているが、ppmオーダー以上含まれているのは、納豆や、クロレラ、海藻、緑黄色野菜などの一部の食品でしかない。しかしながら、いずれの場合も抗骨粗鬆症作用を発揮するためにはあまりにも少ない量である。また、ビタミンKは骨粗鬆症の治療に使われているが、治療を目的とした投与量である1日45mgの摂取では、まれに腹痛、頭痛、発疹などの副作用がみられることがある。これより少ない量では、治療効果が減弱される。魚骨微粉末は単独での骨の改善効果が確認されてはいるが、骨粗鬆症を完全に予防あるいは治療し得るには大量に摂取せねばならず、通常の食生活においては、やはり嗜好上の問題がある。
これら以外に、カルシウムやマグネシウム、ビタミンD、カゼインホスホペプチドなどが、骨を強くする目的で利用されているが、これらの骨強度を高める効果は低い。
従って、高齢化社会の到来に伴なう骨粗鬆症の激増に鑑み、より少ない安全な摂取量の範囲内で、骨粗鬆症の予防、あるいは改善効果をもつ治療剤または機能性食品の開発が切望されているのが実情である。
【0005】
【課題を解決するための手段】
本発明者は、上記課題を解決すべく鋭意研究した結果、有効成分としてビタミンKと特定の骨粉を共に摂取することで、より有効で安全な骨粗鬆症の予防あるいは治療組成物を提供できることを見いだした。
すなわち、本発明は、有効成分としてビタミンKおよびマグネシウム(Mg)含量が100mg/100g以上かつリン(P)含量が10g/100g以上の骨粉、特に魚骨粉を含有することを特徴とする抗骨粗鬆症組成物である。本発明の抗骨粗鬆症組成物は、骨粗鬆症予防および治療用組成物として,また、抗骨粗鬆症食品組成物として用いられる。
【0006】
ビタミンKと上記骨粉の両者が骨組織に対してどの様に作用するかという、相互作用のメカニズムは、以下のようであると推測される。
カルシウムは骨組織を結合させる機能を有し、丈夫な骨とは、内部構造とカルシウムとのバランスによって決まる。
ビタミンKはカルシウムを骨へ沈着させるタンパク質であるオステオカルシンを活性化し、骨を造る細胞である骨芽細胞の働きを促進する。更に骨の内部構造であるコラーゲン繊維を修復し、整える働きをする。一方、マグネシウム、リン等の多くのミネラルを含む天然カルシウム源である魚骨微粉末は、腸管からの吸収効率も高く、骨組織を強固にし得るものとされている。従って、骨粗鬆症の予防あるいは治療に際して、ビタミンKとマグネシウムとリンを所定量含む骨微粉末とを組み合わせた組成物を摂取することにより、骨の内部構造強化とその構造へのカルシウム沈着という相乗効果が発揮されるものと推測される。
その際、魚骨粉と同様に天然カルシウム源である牛骨や貝殻では相乗効果が見られないのは、カルシウム沈着の促進作用を有するマグネシウムとリンを所要量含有しないためと思われる。本発明によれば、相乗効果を得るためには、骨内元素としてのマグネシウム含量は100mg/100g以上かつリン含量は10g/100g以上が必要である。
【0007】
【発明の実施の形態】
本発明に利用されるビタミンKは、ビタミンK1あるいはビタミンK2のいずれでもよく、合成品、天然品いずれも使用できるが、食品として用いる場合、天然由来のものが望ましい。また、微生物由来のビタミンK2の場合、長い食経験のある納豆菌に代表される枯草菌由来のビタミンK2が望ましい。
【0008】
また、本発明品に利用される骨粉としては、魚骨粉が好ましく、製造方法および組成には特に限定されず、魚の骨をそのまま乾燥粉砕したもの、あるいは、適当な手段により精製したものが用いられる。その内、食感、消化吸収性の点からは、粒径が2〜200μm程度に微粉砕したものが特に好ましい。
魚の種類も特に制限はなく、ウナギ、サケ、カツオ、アナゴ、アジ、マグロ、アユ、コイ等淡水魚、海水魚いずれのものも使用できる。なお、これらの魚の骨粉は、1種単独で或いは2種以上を併せて用いてもよい。また、Mg、P含量は1種の骨粉で上記数値を満足するものが好ましいが、2種以上の骨粉で上記数値を満足させてもよく、Mg、P含量の調整のために魚骨粉以外の骨粉を加えてもよい。
本発明によって作られた組成物を摂取する場合、症状、年齢などにより摂取量は異なり、特に限定されない。
【0009】
本発明による組成物は、有効成分としてビタミンKとMg含量が100mg/100g以上かつP含量が10g/100g以上の骨粉とが共に含まれていることが必須であって、カルシウム、マグネシウム、鉄、マンガン、銅、亜鉛などのミネラルや、ビタミンB群、ビタミンD、ビタミンE、ユビキノンなどのビタミン類、さらに大豆イソフラボン等のイソフラボノイド類やフラボノイド類、カゼインホスホペプチドなどのペプチド類、その他、タンパク質や脂質、糖類、オリゴ糖など骨に対する作用に有効と言われている様々な食品成分や食品添加物、さらには化学薬品が含まれていてもなんら構わない。
本発明でいう抗骨粗鬆症組成物においては、乾燥重量中のビタミンK濃度が50 ppm以上で、かつ骨粉が40重量%以上であることが望ましい。好ましくは、ビタミンK濃度が100 ppm以上で、かつ骨粉が50重量%以上、さらに好ましくは、ビタミンK濃度が200 ppm以上で、かつ骨粉が60重量%以上であると、より効果的である。
【0010】
【実施例】
次に、本発明を具体的に説明するために、以下に実施例ならびに製品例を挙げるが、本発明はこれらによって限定されるものではない。なお、以下に示すビタミンK濃度は高速液体クロマトグラフィー法で測定した。
【0011】
実施例1および2
表1に示す配合で、実施例の組成物を調製した。
使用したビタミンK1とビタミンK2はそれぞれ大豆油と納豆油を原料とし、液体クロマトグラフィーにより各々98%以上の純度まで精製して使用した。骨粉は、サケの加工工場における残渣からサケ骨を回収し、乾燥後、平均粒径200μmに微粉砕したものを用いた。この骨粉のMg含量は358mg/100g、P含量は16g/100gであった。
ビタミンK1あるいはビタミンK2とサケ骨粉に、セルロース粉末(旭化成工業株式会社製)、マルトース、α−デキストリンを加え、高速ミキサーにて均一になるまで混合し、各実施例の組成物を調製した。
【0012】
比較例1ないし4
実施例と同様にして、表1に示す配合で各比較例の組成物を調製した。
ビタミンKとサケ骨粉の両成分を含まないもの(比較例1 コントロール)、有効成分としてビタミンK1だけを含むもの(比較例2)、ビタミンK2だけを含むもの(比較例3)、魚骨粉だけを含むもの(比較例4)を実施例と同様の方法により調製した。
実施例ならびに比較例の各組成物について抗骨粗鬆症効果を調べるために、以下の動物実験を行なった。
【0013】
【表1】
【0014】
試験例1:骨粗鬆症改善効果試験
a.試験方法の説明
SD系ラット(22週齢)雌の卵巣を外科的に取り除き、骨粗鬆症のモデルラットを作成した。該卵巣摘出ラットを7匹づつ6群に分け、35日の試験期間中、1日おきに(計17回)、表1に示した実施例1、2ならびに比較例1、2、3、4の各組成物をそれぞれ170mgずつ1mlの生理食塩水に懸濁し、マーゲンゾンデを用いて強制的に経口投与した。飼料はオリエンタル酵母株式会社のマウス・ラット・ハムスター用固形飼料CRF―1を用い、給餌および吸水方法は自由摂取とした。試験期間中、各群間で餌の摂取量に差は認められなかった。
試験開始後35日目にラットの体重を測定した後、大腿骨を取り出した。大腿骨は、接着組織および筋肉を取り除いて分析に使用した。大腿骨の体積を測定した後、エタノールで3回洗浄し、次にアセトンで3回洗浄したのち、一晩乾燥し、その後、重量を測定して大腿骨の乾燥重量を求めた。体積および乾燥重量から、骨密度(乾燥重量g/体積mm3)を測定した。結果を表2に示す。
【0015】
b.試験結果
骨粗鬆症のモデルとして通常使用される卵巣摘出ラットに対する、ビタミンKと魚骨粉による効果は、両者が相乗的に骨密度を改善することを表2の結果が示している。ビタミンK1のみ(比較例2)を投与しても、骨密度はコントロール(比較例1)と比べて改善されなかった。同様に、ビタミンK2のみ(比較例3)の投与においても、骨密度は改善されなかった。また、魚骨粉のみ(比較例4)の投与においても同様に、コントロール(比較例1)と比べて改善効果は少なかった。
ところが、実施例1のようにビタミンK1と魚骨粉を同時に投与すると、コントロール(比較例1)との比較においては勿論、比較例2および3と比べて顕著に骨密度が改善された。すなわち、ビタミンK1と魚骨粉を同時に摂取したことにより、骨に対して相乗効果が発揮され、骨密度が改善されたことが明らかに認められる。
【0016】
さらに、ビタミンK2の場合にも表2に示すようにビタミンK2と魚骨粉の両者を同時に投与した場合(実施例2)、骨代謝に対する顕著な相乗作用が認められた。ビタミンK2は単独で投与(比較例3)しても、コントロール(比較例1)と比べて骨密度の改善は認められなかった。また、魚骨粉単独(比較例4)投与では骨密度の改善効果は少ない。しかしながら、ビタミンK2と魚骨粉を同時に投与すると、高い骨密度改善効果が示された。換言すれば、ビタミンK2および魚骨粉をそれぞれ単独で投与した場合の効果の和よりも、共存させた場合に有意に高い効果が認められた。
【0017】
なお、本発明の効果を視覚的に表示するための実例として、1)正常なラット(図1と図4)、2)骨粗鬆症のモデルラット(図2と図5)、3)骨粗鬆症のモデルラットに実施例1の組成物を上記の条件で摂取させたもの(図3と図6)の3系のラットの大腿骨の骨梁構造のマイクロCTによる三次元構築画像(図1〜3)および大腿骨の内部骨格構造を画像工学的な処理により抽出したもの(図4から6)を示す。
いずれの場合にも骨粗鬆症状態のラットでは、中身がスカスカであるが、ビタミンK1と魚骨粉を同時に摂取させた実施例1の場合には、蜘蛛の巣状になり正常の骨と比べて遜色ないまでに、改善されていることが判る。
【0018】
以上の結果から、本発明により、単独では骨粗鬆症の改善に効果が現れないか、あるいは効果が弱いビタミンK量であっても、所定のMg、P含量の骨粉と共に摂取することにより、両成分が相乗的に作用し、抗骨粗鬆症効果が顕著に促進されることが明らかとなった。
【0019】
【表2】
【0020】
試験例2:安全性試験
本発明品の安全性を確かめるため、実施例1および実施2について変異原性試験および急性毒性試験を行った。
(1)変異原性試験
a.試験方法
細菌を用いる復帰突然変異試験による変異原性を調べた。検定菌はSalmonella typhimurium TA100, TA1535, TA98, TA1537およびEscherichia coli WP2 uvrAを使用した。試験に際して、ニュートリエントブロスNo.2(Oxoid社)を入れたL字型試験管に解凍した菌液を加え、37℃で10時間培養したものを検定菌液とした。被検物質は、ジメチルスルフォキサイドにて、50mg/mlの被検物質調製液として調製し、以下希釈して用いた。
陽性対照物質としては、2−(2−フリル)−3−(5−ニトロ−2−フリル)アクリルアミド、アジ化ナトリウム、9−アミノアクリジン、2−アミノアントラセンを使用した。被検物質をそのまま検定菌に作用させるS9mix無添加試験と、ほ乳類の持つ薬物代謝酵素(S9mix)によって産生される被検物質の代謝物の変異原性を試験するS9mix添加試験からなる。
【0021】
b.試験結果
用いた5種類の検定菌において、S9mix無添加試験およびS9mix添加試験のいずれにおいても溶媒対照値の2倍以上となる変異コロニー数の増加が認められなかったことから、両被検物質とも、用いた試験系において、変異原性を有しない(陰性)と判断された。
【0022】
(2)急性毒性試験
a.試験方法
5週齢の健康なddy系マウスの雌を1群10匹使用した。18時間絶食した後、被検物質が個体体重に対して5g/kgになるように、マーゲンゾンデを用いて強制経口投与した。投与日を0日として各個体の体重を測定しつつ、7日間の一般症状および生死の状態を観察した。この間水と餌は自由に与えた。また、同時に子宮の状態を観察した。
b.試験結果
本試験において、マウスの死亡例は認められず、体重も順調に増加した。また、外観も通常のマウスと何ら変わりがなかった。したがって、両被検物質の、LD50は5g/kgより大きく、安全な組成物であることがわかった。
7日後に解剖し、子宮の状態を観察したところ、何ら異常は認められなかった。
【0023】
【製品例】
製品例1 錠剤
サケ骨を乾燥後粉末化したものと、納豆から抽出したビタミンK2を高濃度に含む油を粉末化したものを主成分とし、以下の処方に基づき錠剤を製造した。
以上の配合で均一に混合した後、打錠した。製品は1粒250mgと小粒で飲みやすく、安全性、携帯性に優れたものであった。
【0024】
製品例2 カプセル剤
ウナギの骨を乾燥粉末化したものと、納豆から抽出したビタミンK2を高濃度に含む油を主成分とし、以下の処方に基づきカプセル剤の原液を処方した。油脂分と粉体であるウナギ骨粉を均一に混合するためにレシチンを使用し、ウナギ骨粉がカプセル内で分離しないように硬化油を使用した。
1カプセル当たりの量が上記比率になるように良く混合し、ゼラチンカプセル化した。
得られたカプセル剤は、安定性が高く、保存性、携帯性に優れたものであった。
【0025】
製品例3 飲料用粉末剤
牛乳などに混合して手軽に摂取できるよう、カツオの骨を乾燥後微粉末化したものと、大豆油脱臭留出物からカラムクロマトグラフィーにより精製したビタミンK1の乳化粉末を主成分とし、下記の処方に基づき製品化した。乳化分散性を高めるために粉末レシチンを使用し、飲みやすいように味付けをした
上記の配合物で均一混合し製品とした。得られた製品は牛乳などに簡単に分散、均一化し、軽い甘さとヨーグルトフレーバーにより、飲みやすいものであった。
【0026】
【発明の効果】
本発明に従って処方された抗骨粗鬆症組成物は、ビタミンKとMg含量が100mg/100g以上かつP含量が10g/100g以上の骨粉を配合することにより、より有効な抗骨粗鬆症効果を得ることができる。
【図面の簡単な説明】
【図1】正常なラットの大腿骨の骨梁構造のマイクロCTによる三次元構築画像である。
【図2】骨粗鬆症のモデルラットの大腿骨の骨梁構造のマイクロCTによる三次元構築画像である。
【図3】骨粗鬆症のモデルラットに実施例1の組成物を上記の条件で摂取させたラットの大腿骨の骨梁構造のマイクロCTによる三次元構築画像である。
【図4】正常なラットの大腿骨の内部骨格構造を画像工学的な処理により抽出した画像である.
【図5】骨粗鬆症のモデルラットの大腿骨の内部骨格構造を画像工学的な処理により抽出した画像である.
【図6】骨粗鬆症のモデルラットに実施例1の組成物を上記の条件で摂取させたラットの大腿骨の内部骨格構造を画像工学的な処理により抽出した画像である.[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an anti-osteoporosis composition containing vitamin K and bone meal, particularly fish bone meal, as active ingredients.
[0002]
[Prior art]
In recent years, with the aging of society, osteoporosis, where bone density decreases and bones become brittle, has become a major problem. When osteoporosis occurs, symptoms such as bone curvature, severe pain, and fractures are observed. In particular, when the femoral neck is fractured, the patient may be bedridden, and an effective treatment method is required.
Osteoporosis therapeutic agents The active vitamin D 3 and female hormones (estrogen), calcitonin, ipriflavone, bisphosphonates, although vitamin K have been developed, treatment of osteoporosis is often difficult, appropriate exercise It is important to strive for prevention by paying attention to foods taken daily.
[0003]
In order to prevent osteoporosis, intake of dairy products and fish containing a large amount of calcium is recommended for diet. Furthermore, the use of health foods including calcium, magnesium, vitamin D, and casein phosphopeptide (which is said to have an effect of promoting absorption of calcium from the intestinal tract) is also recommended.
In recent years, attention has been paid to the action of vitamin K on bones, and various utilization methods have been studied. Vitamin K includes vitamin K 1 (ferroquinone), which is mainly produced by plants, and vitamin K 2 (menaquinone), which is mainly produced by microorganisms. Furthermore, vitamin K 2 has menaquinone (MK) -1 14 is classified. Vitamin K is widely present in foods, but its content is very small.
On the other hand, recently, it has been noted that fish bone powder such as eel bone fine powder has a bone improving action.
[0004]
[Problems to be solved by the invention]
Vitamin K is contained in foods in trace amounts, but only parts of foods such as natto, chlorella, seaweed and green-yellow vegetables contain more than ppm order. However, in any case, the amount is too small to exert an anti-osteoporosis effect. Vitamin K is used for the treatment of osteoporosis. However, ingestion of 45 mg per day, which is a dose intended for treatment, rarely causes side effects such as abdominal pain, headache, and rash. Less than this will reduce the therapeutic effect. Fish bone fine powder alone has been confirmed to improve bone alone, but it must be consumed in large quantities in order to completely prevent or treat osteoporosis. There's a problem.
In addition to these, calcium, magnesium, vitamin D, casein phosphopeptide, and the like are used for the purpose of strengthening bones, but their effect of increasing bone strength is low.
Therefore, in view of the dramatic increase in osteoporosis accompanying the arrival of an aging society, the development of therapeutic agents or functional foods that have the effect of preventing or improving osteoporosis within the range of safer intake is eagerly desired. Is the actual situation.
[0005]
[Means for Solving the Problems]
As a result of earnest research to solve the above-mentioned problems, the present inventor has found that a more effective and safe composition for preventing or treating osteoporosis can be provided by ingesting vitamin K and specific bone powder as active ingredients. .
That is, the present invention comprises an anti-osteoporosis composition comprising, as an active ingredient, bone powder having vitamin K and magnesium (Mg) content of 100 mg / 100 g or more and phosphorus (P) content of 10 g / 100 g or more, particularly fish bone powder. It is a thing. The anti-osteoporosis composition of the present invention is used as a composition for preventing and treating osteoporosis and as an anti-osteoporosis food composition.
[0006]
It is presumed that the mechanism of interaction, which is how both vitamin K and the above bone meal act on bone tissue, is as follows.
Calcium has a function of binding bone tissue, and a strong bone is determined by a balance between internal structure and calcium.
Vitamin K activates osteocalcin, a protein that deposits calcium on bone, and promotes the action of osteoblasts, which are bone-forming cells. Furthermore, it works to repair and arrange the collagen fibers that are the internal structure of bone. On the other hand, fish bone fine powder, which is a natural calcium source containing many minerals such as magnesium and phosphorus, has high absorption efficiency from the intestinal tract and can strengthen bone tissue. Therefore, in the prevention or treatment of osteoporosis, by taking a composition comprising a combination of bone fine powder containing a predetermined amount of vitamin K, magnesium and phosphorus, a synergistic effect of strengthening the internal structure of the bone and depositing calcium on the structure is obtained. It is presumed to be demonstrated.
At that time, the reason that the synergistic effect is not observed in the beef bones and shells which are natural calcium sources like the fish bone powder seems to be because it does not contain the required amount of magnesium and phosphorus which have the action of promoting calcium deposition. According to the present invention, in order to obtain a synergistic effect, the magnesium content as an intraosseous element needs to be 100 mg / 100 g or more and the phosphorus content needs to be 10 g / 100 g or more.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
Vitamin K used in the present invention may be either vitamin K 1 or vitamin K 2 , and both synthetic products and natural products can be used. Also, in the case of vitamin K 2 derived from a microorganism, vitamin K 2 derived from Bacillus subtilis typified by Bacillus natto with long eaten it is desirable.
[0008]
Further, the bone meal used in the present invention is preferably fish bone meal, and the production method and composition are not particularly limited, and those obtained by pulverizing fish bones as they are, or those purified by appropriate means are used. . Among them, from the viewpoints of texture and digestibility and absorption, those finely pulverized to a particle size of about 2 to 200 μm are particularly preferable.
The type of fish is not particularly limited, and any of freshwater fish such as eel, salmon, skipjack, eel, horse mackerel, tuna, ayu, carp, and saltwater fish can be used. In addition, you may use these fish bone meal individually by 1 type or in combination of 2 or more types. The Mg and P contents are preferably one kind of bone meal that satisfies the above numerical values, but the above numerical values may be satisfied with two or more kinds of bone meal, and other than fish and bone meal for adjusting the Mg and P contents. Bone meal may be added.
When ingesting the composition made according to the present invention, the intake varies depending on symptoms, age, etc., and is not particularly limited.
[0009]
The composition according to the present invention must contain both vitamin K as an active ingredient and bone meal having a Mg content of 100 mg / 100 g or more and a P content of 10 g / 100 g or more, and calcium, magnesium, iron, Minerals such as manganese, copper, zinc, vitamins such as vitamin B group, vitamin D, vitamin E, ubiquinone, isoflavonoids such as soy isoflavone, flavonoids, peptides such as casein phosphopeptide, other proteins, It does not matter if it contains various food ingredients and food additives, such as lipids, saccharides and oligosaccharides, which are said to be effective for action on bones, and chemicals.
In the anti-osteoporosis composition referred to in the present invention, it is desirable that the vitamin K concentration in the dry weight is 50 ppm or more and the bone powder is 40% by weight or more. Preferably, the vitamin K concentration is 100 ppm or more, the bone meal is 50% by weight or more, and more preferably, the vitamin K concentration is 200 ppm or more and the bone meal is 60% by weight or more.
[0010]
【Example】
Next, in order to specifically describe the present invention, examples and product examples are given below, but the present invention is not limited to these examples. The vitamin K concentration shown below was measured by high performance liquid chromatography.
[0011]
Examples 1 and 2
Compositions of Examples were prepared with the formulations shown in Table 1.
The vitamin K 1 and vitamin K 2 used were made from soybean oil and natto oil, respectively, and purified to a purity of 98% or more by liquid chromatography. As the bone meal, salmon bone was collected from the residue in the salmon processing factory, dried and then finely pulverized to an average particle size of 200 μm. This bone meal had a Mg content of 358 mg / 100 g and a P content of 16 g / 100 g.
Cellulose powder (made by Asahi Kasei Kogyo Co., Ltd.), maltose and α-dextrin were added to vitamin K 1 or vitamin K 2 and salmon bone powder, and mixed with a high-speed mixer until uniform to prepare the compositions of the respective examples. .
[0012]
Comparative Examples 1 to 4
In the same manner as in Examples, compositions of Comparative Examples were prepared with the formulations shown in Table 1.
What does not contain both components of vitamin K and salmon bone meal (Comparative Example 1 control), contains only vitamin K 1 as an active ingredient (Comparative Example 2), contains only vitamin K 2 (Comparative Example 3), fish bone meal (Comparative Example 4) containing only this was prepared in the same manner as in Examples.
In order to examine the anti-osteoporosis effect of the compositions of Examples and Comparative Examples, the following animal experiments were conducted.
[0013]
[Table 1]
[0014]
Test Example 1: Osteoporosis Improvement Effect Test a. Description of Test Method SD rat (22 weeks old) female ovaries were surgically removed to create osteoporosis model rats. The ovariectomized rats were divided into 6 groups of 7 animals, and every other day (total 17 times) during the 35-day test period, Examples 1 and 2 and Comparative Examples 1, 2, 3, 4 shown in Table 1 were used. Each composition was suspended in 1 ml of physiological saline with 170 mg each and forcibly administered orally using a margensonde. The feed used was the solid feed CRF-1 for mice, rats, and hamsters of Oriental Yeast Co., Ltd., and the feeding and water absorption methods were freely ingested. There was no difference in food intake between groups during the study period.
On the 35th day after the start of the test, the weight of the rat was measured, and then the femur was removed. The femur was used for analysis with the adhesive tissue and muscle removed. After measuring the volume of the femur, it was washed three times with ethanol, then washed three times with acetone, dried overnight, and then weighed to determine the dry weight of the femur. From the volume and dry weight, bone density (dry weight g / volume mm 3 ) was measured. The results are shown in Table 2.
[0015]
b. Test results The effects of vitamin K and fish bone powder on the ovariectomized rats normally used as a model for osteoporosis show that both synergistically improve bone density. Even when only vitamin K 1 (Comparative Example 2) was administered, the bone density was not improved compared to the control (Comparative Example 1). Similarly, administration of vitamin K 2 alone (Comparative Example 3) did not improve bone density. Similarly, the administration of fish bone meal alone (Comparative Example 4) was less effective for improvement than the control (Comparative Example 1).
However, when vitamin K 1 and fish bone meal were administered simultaneously as in Example 1, the bone density was remarkably improved as compared with Comparative Examples 2 and 3 as well as in comparison with Control (Comparative Example 1). That is, it can be clearly seen that the simultaneous intake of vitamin K 1 and fish bone meal exerted a synergistic effect on bone and improved bone density.
[0016]
Further, in the case of vitamin K 2 as shown in Table 2, when both vitamin K 2 and fish bone meal were administered simultaneously (Example 2), a remarkable synergistic effect on bone metabolism was observed. Even when vitamin K 2 was administered alone (Comparative Example 3), no improvement in bone density was observed compared to the control (Comparative Example 1). In addition, administration of fish bone meal alone (Comparative Example 4) has little effect on improving bone density. However, when vitamin K 2 and fish bone meal were administered simultaneously, a high bone density improving effect was shown. In other words, a significantly higher effect was observed when coexisting than the sum of the effects when vitamin K 2 and fish bone meal were each administered alone.
[0017]
As examples for visually displaying the effects of the present invention, 1) normal rats (FIGS. 1 and 4), 2) osteoporosis model rats (FIGS. 2 and 5), and 3) osteoporosis model rats A three-dimensional construction image (FIGS. 1 to 3) by micro CT of the trabecular structure of the femur of a three-system rat in which the composition of Example 1 was ingested under the above conditions (FIGS. 3 and 6) The internal skeleton structure of the femur is extracted by image engineering processing (FIGS. 4 to 6).
In either case, the rat in osteoporosis is Sukasuka, but in the case of Example 1 in which vitamin K 1 and fish bone meal were ingested at the same time, it became a spider web and was darker than normal bone. It can be seen that it has been improved.
[0018]
From the above results, according to the present invention, even if the amount of vitamin K is not effective in improving osteoporosis by itself or is weakly effective, both components can be obtained by ingesting together with bone powder having predetermined Mg and P contents. It was revealed that they act synergistically and the anti-osteoporosis effect is significantly promoted.
[0019]
[Table 2]
[0020]
Test Example 2: Safety Test In order to confirm the safety of the product of the present invention, a mutagenicity test and an acute toxicity test were conducted on Example 1 and Example 2.
(1) Mutagenicity test a. Test method Mutagenicity was examined by a reverse mutation test using bacteria. Salmonella typhimurium TA100, TA1535, TA98, TA1537 and Escherichia coli WP2 uvrA were used as assay bacteria. During the test, the thawed bacterial solution was added to an L-shaped test tube containing Nutrient Broth No. 2 (Oxoid) and cultured at 37 ° C. for 10 hours to obtain a test bacterial solution. The test substance was prepared as a test substance preparation solution of 50 mg / ml with dimethyl sulfoxide and diluted below.
As a positive control substance, 2- (2-furyl) -3- (5-nitro-2-furyl) acrylamide, sodium azide, 9-aminoacridine, and 2-aminoanthracene were used. It consists of an S9mix additive-free test in which the test substance is allowed to act on the test bacteria as it is, and an S9mix addition test that tests the mutagenicity of the metabolite of the test substance produced by the drug metabolizing enzyme (S9mix) possessed by mammals.
[0021]
b. Test results In the 5 types of test bacteria used, no increase in the number of mutant colonies that was more than twice the solvent control value was observed in both the S9mix non-addition test and the S9mix addition test. Both substances were judged not to be mutagenic (negative) in the test system used.
[0022]
(2) Acute toxicity test a. Test method A group of 10 females of 5 weeks old healthy ddy mice were used. After fasting for 18 hours, the test substance was forcibly administered orally using a magensonde so that the test substance was 5 g / kg relative to the individual body weight. While observing the body weight of each individual on the day of administration as day 0, the general symptoms and life and death conditions for 7 days were observed. During this time, water and food were given freely. At the same time, the condition of the uterus was observed.
b. Test Results In this test, no mice died and the body weight increased steadily. Also, the appearance was no different from normal mice. Therefore, LD 50 of both test substances was larger than 5 g / kg, and it was found that these were safe compositions.
After 7 days, the patient was dissected and the condition of the uterus was observed, and no abnormality was found.
[0023]
[Product example]
Product Example 1 Tablets were produced on the basis of the following formulation, mainly composed of tableted salmon bone dried and powdered, and powdered oil containing vitamin K 2 extracted from natto in high concentration.
After uniformly mixing with the above formulation, tableting was performed. The product was as small as 250 mg per tablet and was easy to drink, and was excellent in safety and portability.
[0024]
Product Example 2 Capsule eel bone powder and oil containing vitamin K 2 extracted from natto in high concentration were the main ingredients, and a capsule stock solution was formulated based on the following formulation. Lecithin was used to uniformly mix the fat and powder and eel bone meal, and hardened oil was used so that the eel bone meal was not separated in the capsule.
The mixture was mixed well so that the amount per capsule was the above ratio, and gelatin was encapsulated.
The obtained capsule was highly stable and excellent in storage stability and portability.
[0025]
Product Example 3 Drying powdered bonito bone to make it easy to mix with powdered beverages such as milk for milk, and emulsification of vitamin K 1 purified by column chromatography from soybean oil deodorized distillate Based on the following formulation, it was commercialized with powder as the main component. Powdered lecithin was used to enhance emulsifying dispersibility and seasoned to make it easy to drink
The product was uniformly mixed with the above blend to obtain a product. The obtained product was easily dispersed and homogenized in milk and the like, and it was easy to drink due to its light sweetness and yogurt flavor.
[0026]
【The invention's effect】
The anti-osteoporosis composition prescribed | regulated according to this invention can acquire a more effective anti-osteoporosis effect by mix | blending vitamin K and bone meal with Mg content of 100 mg / 100g or more and P content of 10 g / 100g or more.
[Brief description of the drawings]
FIG. 1 is a three-dimensional constructed image by micro CT of a trabecular structure of a normal rat femur.
FIG. 2 is a three-dimensional constructed image by micro CT of the trabecular structure of the femur of an osteoporotic model rat.
FIG. 3 is a three-dimensional constructed image by micro CT of the trabecular structure of the femur of a rat in which the model rat of osteoporosis was ingested with the composition of Example 1 under the above conditions.
FIG. 4 is an image obtained by image engineering processing of the internal skeletal structure of a normal rat femur.
FIG. 5 is an image obtained by extracting the internal skeletal structure of the femur of an osteoporotic model rat by image engineering processing.
FIG. 6 is an image obtained by extracting the internal skeletal structure of the femur of a rat in which the composition of Example 1 was ingested in an osteoporosis model rat under the above-described conditions by image engineering processing.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001256462A JP4131443B2 (en) | 2001-08-27 | 2001-08-27 | Anti-osteoporosis composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001256462A JP4131443B2 (en) | 2001-08-27 | 2001-08-27 | Anti-osteoporosis composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003063970A JP2003063970A (en) | 2003-03-05 |
| JP4131443B2 true JP4131443B2 (en) | 2008-08-13 |
Family
ID=19084273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001256462A Expired - Lifetime JP4131443B2 (en) | 2001-08-27 | 2001-08-27 | Anti-osteoporosis composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4131443B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2802786C1 (en) * | 2022-11-21 | 2023-09-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Южно-Уральский государственный университет (национальный исследовательский университет)" ФГАОУ ВО "ЮУрГУ (НИУ)" | Method for grinding collagen-containing media and a tool for its implementation |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090023562A (en) * | 2006-06-23 | 2009-03-05 | 제이-오일 밀스, 인코포레이티드 | Testosterone increasing agents |
| WO2011031601A2 (en) * | 2009-09-14 | 2011-03-17 | Nestec S.A. | Nutritional compositions including exogenous vitamin k2 |
| CN112998221A (en) * | 2021-04-09 | 2021-06-22 | 周洪光 | Preparation method of bone strengthening powder electuary for treating osteoporosis |
| CN117502645A (en) * | 2023-11-13 | 2024-02-06 | 深圳中科生物药业有限公司 | Dietary nutritional composition for preventing and treating osteoporosis and preparation method thereof |
-
2001
- 2001-08-27 JP JP2001256462A patent/JP4131443B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2802786C1 (en) * | 2022-11-21 | 2023-09-01 | Федеральное государственное автономное образовательное учреждение высшего образования "Южно-Уральский государственный университет (национальный исследовательский университет)" ФГАОУ ВО "ЮУрГУ (НИУ)" | Method for grinding collagen-containing media and a tool for its implementation |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003063970A (en) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Asaikkutti et al. | Effect of different levels dietary vitamin C on growth performance, muscle composition, antioxidant and enzyme activity of freshwater prawn, Macrobrachium malcolmsonii | |
| JP2012176949A (en) | Use of vitamin d compound | |
| Shi et al. | Selenium from beef is highly bioavailable as assessed by liver glutathione peroxidase (ec 1· 11· 1· 9) activity and tissue selenium | |
| WO2011077800A1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| CA2603518C (en) | Nutrient composition for promoting collagen production | |
| US5002780A (en) | Magnesium salt of a fatty acid acyl lactylate | |
| JPH07252156A (en) | Medicine for prevention and therapy of osteoporosis | |
| CN102281769A (en) | Method for improving animal liver and immune function | |
| JP3749978B2 (en) | Bone formation enhancing composition exhibiting anti-osteoporosis effect | |
| JP3459932B2 (en) | Anti-osteoporosis composition | |
| JP4131443B2 (en) | Anti-osteoporosis composition | |
| CN110214942A (en) | A kind of hyperthyroidism tailored version Nutrition formula and preparation method thereof | |
| JP2005312365A (en) | Lysine-containing antiobesity or antilipemic food, feed and supplement | |
| JP2004000171A (en) | Functional food product containing maca | |
| JP3250071B2 (en) | Anti-osteoporosis composition | |
| JP2567231B2 (en) | Dietary supplement for enhancing endurance | |
| Failla et al. | Total body content of copper and other essential metals in rats fed fructose or starch | |
| KR19990080441A (en) | Health supplement composition for growth | |
| JP3248170B2 (en) | Food containing chondroitin sulfate protein complex | |
| JPS6140766A (en) | Nutrient-assistant food | |
| JP2002142723A (en) | Ingredients for diet food and diet food | |
| NL9401958A (en) | Milk product enriched with eggshell flour. | |
| JPH09132531A (en) | Composition for additive to liquid food and liquid food | |
| JP2002281941A (en) | Food preparation with high calcium content | |
| Oyegoke et al. | Anthropometric and Biochemical Assessment of Yahauri Spice Meal-Based Diet on Selected Tissues of Female Wistar Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20040917 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050927 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20070612 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20070705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070718 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070918 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071017 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070918 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071115 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080311 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080514 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080519 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110606 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4131443 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110606 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110606 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120606 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120606 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130606 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130606 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130606 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |